Skip to main content

Exametazime Pregnancy and Breastfeeding Warnings

Brand names: Ceretec, Drax Exametazime

Exametazime Pregnancy Warnings

FDA pregnancy category: C

Potential benefit should outweigh the potential risk.

Animal reproduction studies have not been conducted.

It is not known whether Tc99m exametazime can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity.

FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Exametazime Breastfeeding Warnings

The manufacturer recommends formula feedings for 60 hours following administration.

Breast-feeding is not recommended during use of exametazime.

Excreted into human milk: Yes (technetium Tc99m); unknown (exametazime)
Excreted into animal milk: Unknown

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Product Information. Ceretec (exametazime). GE Healthcare. 2012.

References for breastfeeding information

  1. Product Information. Ceretec (exametazime). GE Healthcare. 2012.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.